Special Issue

Modern Approach to Neuroendocrine Neoplasms Diagnosis and Treatment

Message from the Guest Editors

The diagnosis and treatment of neuroendocrine neoplasms (NENs) remains a challenging issue, mainly due to the heterogeneous character of the disease and variations in the treatment response. Current treatment options not only include classic surgery, somatostatin analogs, radioligand therapy, chemotherapy and targeted therapy, but also careful observation or minimally invasive interventions. Hence, we would like to invite all researchers working in the field of neuroendocrine neoplasms to contribute to this Special Issue of *Pharmaceuticals*, entitled "Modern Approaches" to the Diagnosis and Treatment of Neuroendocrine Neoplasms", and share their experiences, results, or insights into the disease. Pharmaceuticals offers the publication of high-quality papers in the field, and currently boasts a journal impact factor of 4.6. We hope that the given deadline-30 June 2024-will be acceptable for all those interested in publishing in this Special Issue. However, an extension of the deadline for the preparation of high-value publications is possible.

Guest Editors

Prof. Dr. Marek Saracyn

Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine-National Research Institute, 04-141 Warsaw, Poland

Dr. Adam Daniel Durma

Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine-National Research Institute, 04-141 Warsaw, Poland

Deadline for manuscript submissions

closed (25 January 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/192496

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

